Literature DB >> 24634108

Bronchiolitis obliterans with allogeneic hematopoietic cell transplantation: a 10-year experience of the Okayama BMT Group.

Nobuharu Fujii1, Koichi Nakase, Shoji Asakura, Keitaro Matsuo, Yuichiro Nawa, Kazutaka Sunami, Hisakazu Nishimori, Ken-Ichi Matsuoka, Eisei Kondo, Yoshinobu Maeda, Katsuji Shinagawa, Masamichi Hara, Mitsune Tanimoto.   

Abstract

Bronchiolitis obliterans (BO) is a devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT). We retrospectively studied 465 patients who underwent HSCT in the Okayama BMT Group between 2000 and 2009, and describe the detailed clinical features of 13 patients with BO. The 5-year cumulative incidence of BO was 3.43 %. The median time from transplantation to onset of BO was 15 months. In seven of the 13 patients, the primary symptom was only cough, indicating that cough was an important initial symptom for early diagnosis. The median duration from the onset of BO to the requirement of O2 supplementation was 13 months and the main cause of death was respiratory failure. History of chronic graft-versus-host disease was a significant risk factor. Furthermore, female recipients were at greater risk of BO than male recipients; however, no other previously reported risk factors were detected. It is currently difficult to prevent BO on the basis of the reported risk factors. A novel strategy for the early diagnosis and treatment of BO is required.

Entities:  

Mesh:

Year:  2014        PMID: 24634108     DOI: 10.1007/s12185-014-1556-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  Inhaled corticosteroids stabilize constrictive bronchiolitis after hematopoietic stem cell transplantation.

Authors:  L Bashoura; S Gupta; A Jain; D R Couriel; K V Komanduri; G A Eapen; A Safdar; K R Broglio; R Adachi; B F Dickey
Journal:  Bone Marrow Transplant       Date:  2007-10-15       Impact factor: 5.483

Review 2.  An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome.

Authors:  Angela Panoskaltsis-Mortari; Matthias Griese; David K Madtes; John A Belperio; Imad Y Haddad; Rodney J Folz; Kenneth R Cooke
Journal:  Am J Respir Crit Care Med       Date:  2011-05-01       Impact factor: 21.405

3.  Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial.

Authors:  Birte Friedrichs; André Tichelli; Andrea Bacigalupo; Nigel H Russell; Tapani Ruutu; Michael Y Shapira; Meral Beksac; Dirk Hasenclever; Gérard Socié; Norbert Schmitz
Journal:  Lancet Oncol       Date:  2010-01-30       Impact factor: 41.316

4.  Azithromycin in bronchiolitis obliterans complicating bone marrow transplantation: a preliminary study.

Authors:  M Khalid; A Al Saghir; S Saleemi; S Al Dammas; M Zeitouni; A Al Mobeireek; N Chaudhry; E Sahovic
Journal:  Eur Respir J       Date:  2005-03       Impact factor: 16.671

5.  Effects of azithromycin in bronchiolitis obliterans syndrome after hematopoietic SCT--a randomized double-blinded placebo-controlled study.

Authors:  D C L Lam; B Lam; M K Y Wong; C Lu; W Y Au; E W C Tse; A Y H Leung; Y L Kwong; R H S Liang; W K Lam; M S M Ip; A K W Lie
Journal:  Bone Marrow Transplant       Date:  2011-02-14       Impact factor: 5.483

6.  Late-onset noninfectious pulmonary complications after allogeneic bone marrow transplantation.

Authors:  A Palmas; A Tefferi; J L Myers; J P Scott; S J Swensen; M G Chen; D A Gastineau; M A Gertz; D J Inwards; M Q Lacy; M R Litzow
Journal:  Br J Haematol       Date:  1998-03       Impact factor: 6.998

7.  Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes.

Authors:  Arkadiusz Z Dudek; Hemchandra Mahaseth; Todd E DeFor; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2003-10       Impact factor: 5.742

8.  Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

Authors:  H M Shulman; K M Sullivan; P L Weiden; G B McDonald; G E Striker; G E Sale; R Hackman; M S Tsoi; R Storb; E D Thomas
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

9.  Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients.

Authors:  B C Norman; D A Jacobsohn; K M Williams; B K C Au; M A Au; S J Lee; C K Moravec; J W Chien
Journal:  Bone Marrow Transplant       Date:  2010-12-06       Impact factor: 5.483

Review 10.  Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.

Authors:  G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483

View more
  3 in total

1.  Detection of pulse rate elevation by Apple Watch in a patient with bronchiolitis obliterans syndrome after allogeneic stem cell transplantation.

Authors:  Toshiki Mushino; Akinori Nishikawa; Takayuki Hiroi; Yoriko Matsuyama; Hiroki Hosoi; Shogo Murata; Shinobu Tamura; Takashi Sonoki
Journal:  Ann Hematol       Date:  2021-07-31       Impact factor: 3.673

2.  Efficacy and safety of high-dose budesonide/formoterol in patients with bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplant.

Authors:  Kyung Hoon Kim; Jongmin Lee; Hee-Je Kim; Seok Lee; Yoo-Jin Kim; Jong Hyuk Lee; Chin Kook Rhee
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

3.  Prevention of non-infectious pulmonary complications after intra-bone marrow stem cell transplantation in mice.

Authors:  Yoshiko Yamasuji-Maeda; Hisakazu Nishimori; Keisuke Seike; Akira Yamamoto; Hideaki Fujiwara; Taiga Kuroi; Kyosuke Saeki; Haruko Fujinaga; Sachiyo Okamoto; Ken-Ichi Matsuoka; Nobuharu Fujii; Takehiro Tanaka; Masahiro Fujii; Katsumi Mominoki; Takuro Kanekura; Yoshinobu Maeda
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.